Diabetes drug semaglutide may reshape fat in heart and muscles
NCT ID NCT07065383
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is looking at how semaglutide, a drug used for diabetes and weight loss, changes the amount of fat stored inside the heart and leg muscles. Researchers want to see if semaglutide can shift fat away from these organs, which might improve health beyond just lowering blood sugar. The study will involve 60 adults with type 2 diabetes who are not very active, and they will receive semaglutide along with diet advice and either general physical activity encouragement or a supervised exercise program.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Semaglutide
What this could lead to
If successful, this could show that semaglutide helps rebalance fat storage in the heart and muscles, potentially leading to better diabetes management and reduced cardiovascular risk.
What could go wrong
This is a small, early-stage study (60 participants) focused on measuring fat changes, not clinical outcomes. The results may not apply to all people with type 2 diabetes, and semaglutide can cause side effects like nausea and vomiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cardiac Research Office, Aberdeen Royal Infirmary
RECRUITINGAberdeen, Aberdeenshire, AB25 2ZD, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••